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We studied the regulation of group II phospholip~ 4 (PLA+) gene in vivo, using endotoxin shock rat as a model for systemic infla~ation. 
Administration of endotoxin into rats increased PL4 activity in the plasma, as described by Vadas and Hay, using endotoxin-challenged rabbit. 
Specific absorption of this activity by anti-PL&-II antibody indicated that the refeased PL4 was PL4-II. The levels of PL&-II mRNA were 
elevated in the aorta, spleen, lung, and thymus but not in the liver and kidney. The tissues with high PL&,-II mRNA contents released a greater 
amount of PLA$I than the tissues of control rats. These results suggest hat in endotoxin shock rats, PL4-II is synthesized e novo in the above 
tissues and released into circulation. Furthermore, our present study demonstrates that glucocorticcid suppresses the enhanced expression of the 
PL&,-II gene in the tissues of endotoxin shock rats. 
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1. INTRODUCTION 
Several lines of evidence have suggested that 
secretory phospholipase A2 (PLA2) plays an important 
role in the pathogenesis of inflammatory diseases (for 
review see [2]). In the serum of Gram-negative septic- 
shock patients and experimental endotoxin-shock 
animals, levels of PLA2 activity were significantly 
elevated [ 1,3,41. Furthermore, intravenous infusion of 
PLA2 into animals caused symptoms of septic shock 
[1,5,6]. Based on these findings, Vadas et al. have pro- 
posed that extracellul~ PLAz is a primary mediator of 
septic shock and endotoxin shock 171. However, the 
type of circulating PLA2, the source of the PLA2, and 
the mechanism of the elevation of the PLA;! levels are 
undefined as yet. 
Two types of mammalian secretory PLA2, termed 
group I and II, have been well characterized on the 
molecular basis. Group 1 PLAz is secreted from the ceils 
as an inactive pro-enzyme, but group II PLA2 
(PLAz-II) as an active enzyme [8,9]. We have recently 
clarified that some inflammatory factors increased 
PLA2-II mRNA levels, which resulted in enhanced 
secretion of PLA2-II from cultured rat smooth muscle 
ceils [lo, 111. This finding strongly suggests that 
PLA2-II, which is often found in the extracellular fluid 
of some inflamed sites [12-141, participates in the pro- 
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gress of in~ammatory processes. In this context, we 
thought that PLA2-II might also be involved in en- 
dotoxin shock. In this study, we examined the activa- 
tion of PLA2-II gene in several tissues of endotoxin- 
challenged rats and investigated the effect of glucocor- 
ticoid on the activation. 
2. MATERIALS AND METHODS 
2.1. Administration of endotoxin 
Male Sprague-Dawley rats weighing 280-320 g were used for all 
studies. Rats were injected in~avenously with 5 mgfkg endotoxin 
(~scherjch~a coli, OSS:BS, Sigma) dissolved in saline. Control rats 
received sterile saline. If necessary, rats were injected intraperitoneal- 
ly with 10 mg/kg dexamethasone (Sigma) suspended in saline 30 min 
prior to administration of endotoxin. At timed intervals, blood ob- 
tained by puncture of the abdominal aorta was collected into plastic 
syringes containing 10 mM EDTA and 1 pg/ml prostaglandin Ei to 
prevent blood coagulation and platelet activation. The blood was cen- 
trifuged (400 x g) at 4’C to obtain plasma. Tissues were immediately 
frozen with solid CO2 just after extraction. 
2.2. PLAl activity assay 
PI-AZ activity was measured using [3H]oleic acid-labeled (Amer- 
sham Corp.) Ewherichia coli phospho~pids as substrates [IS], The 
assay conditions are described elsewhere f10, I 11. 
2.3. Inhibition of PLAz activity by antibody 
Rabbit anti-rat PLAz-II antibody was produced as described 
previously [lo,1 11. Samples were incubated with several dilutions of 
the antibody (7.3 mg IgG/ml) for 1 h, and PLA2 activity was assayed. 
Rat pancreatic PLAz was purified as described by Ono et al [16]. 
2.4. Release of PLA2 from tissues 
About 0.2 g of aorta and thymus from control or endotoxin-treated 
rats was minced and incubated for 30 min in 2 ml of Dulbecco’s 
modified Eagle’s medium containing 0.1 mg/ml bovine serum 
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Table I 
Plasma PLAz activity in endotoxia-treated rats 
Time PLA2 activity 
00 (dpm) 
0 401 +: 87 
2 758 f 123 
4 1135 f 297 
8 2243 f 45 
Data are the mean I SD (n = 3). 
albumin, At the end of the incubation, the medium was collected and 
assayed for PLAz activity. 
2.5. RNA blotting 
Total RNA was prepared from the tissues by the method of 
Chomoczynski and Sacchi 1171. The RNA (10 pg) was fractionated on 
a 1% agarose gel containing 2.2 M formaldehyde. Hybridization of 
the RNA transferred to a nylon membrane was performed as describ- 
ed by Church and Gilbert [18], using rat PLAz-II cI?NA [9J labeled 
with fcr-3zP]dCTP jDu Pent-New England Nuclear, 5ooO Wmmol) 
as a probe. 
3. RESULTS 
As illustrated in Table I, PLAz activity in plasma was 
elevated in endotoxin-shock rats, which was induced by 
i.v. challenge with 5 mg/kg of E;: coli endotoxin. In 
order to clarify the type of the plasma PLA2, we carried 
out an inhibition study of the PLA2 activity with a 
specific polyclonal antibody against rat PLAz-II 
[lO,ll], Fig. 1 shows that the antibody specifically in- 
, 
-Ab ?/los 1UOS Hid, l/103 lil0 
Antibody dilution 
Fig. 1. Inhibition of plasma PLAz by anti-PLAz-II antibody+ Blood 
plasma collected 8 h after endotoxin challenge (0) or rat pancreatic 
PLAz (0) was incubated for 1 h at 25°C with several dilutions of anti- 
PLAz-II antibody, and assayed for PLAz activity. 
hibited the plasma PLA2 activity but did not affect the 
activity of rat pancreatic PLAz which belongs to group 
I PLA2. These results indicated that the PLA2 whose 
levels in plasma were elevated by the endotoxin 
challenge was PLAz-II. 
In previous studies [IO, 111, we have suggested that 
vascular smooth muscle cells are major PLAz-II pro- 
ducing cells. Therefore, we next studied PLA2-II 
mRNA levels in aorta of endotoxin-administered rats 
(Fig. 2). In the aorta of control rats, we hardly detected 
PLAz-II mRNA by RNA blotting analysis. The mRNA 
Fig. 
24 
2. Increase of PLAz-IX mRNA in aorta of endoto~in~~e~ed rats. Total RNA was prepared from aorta of control rats or endot 
administered rats. The RNA (10 pg) was analyzed by RNA bletting analysis as described in section 2, 
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Fig. 3. Increase of PLAz-II rnRNA in tissues of endotoxin-treated rats. The tissues indicated in the figure were obtained from control rats or 
endotoxin-treated rats 24 h after administration of endotoxin. The RNA (10 Gg) prepared from the tissues was analyzed as described in the legend 
of Fig. 2. 
levels in aorta were markedly elevated upon administra- 
tion of endotoxin. Furthermore, PLAz-II mRNA levels 
also increased in the spleen, lung, and thymus by the en- 
dotoxin administration as shown in Fig. 3. However, 
PLA2-II mRNA did not significantly increase in liver 
and kidney. 
In order to further confirm the elevated synthesis of 
PLA2-II protein by the tissues, PLA2 activity released 
from the tissues during 30 min incubation was 
measured. As illustrated in Table II, the aorta and the 
thymus of endotoxin-challenged rats secreted greater 
amounts of PLAz activity than the tissues of control 
rats. The PLAz activity released from the tissues was 
completely inhibited by the anti-PLAz-II antibody 
(data not shown), indicating that the PLA2 released 
from the tissues was PLA2-II. These findings verified 
that elevated mRNA levels in the tissues resulted in in- 
creased secretion of PLA2-II into extracellular spaces. 
Vadas and Hay [l] have previously demonstrated 
that glucocorticoids inhibited a rise in plasma PLAz ac- 
tivity in endotoxin-administered rabbits. On the other 
hand, we have recently reported that glucocorticoids in- 
hibit the synthesis of PLA2-II in cultured smooth mus- 
cle cells [I 11. We thereby studied the effect of pretreat- 
ment of rats with dexamethasone, a synthetic glucocor- 
ticoid, on the increase of PLAz-II mRNA in tissues 
evoked by endotoxin. Fig. 4 shows that the pretreat- 
ment of rats with 10 mg/kg dexamethasone alone had 
no effect on the mRNA levels, but it severely depressed 
the elevation of PLA2-II mRNA levels by endotoxin in 
aorta, lung, and thymus. 
Table II 
Release of PLAr from tissues of endotoxin-treated rats 
Tissue PLA2 activity (dpm) 
Control Endotoxin-treated 
Aorta 729 f 45 3411 f 561 
Thymus 1414 f 686 3583 f 788 
PLA2 activity released uring 30 min incubation from tissues of con- 
trol rats or endotoxin-treated rats was measured as described in sec- 
tion 2. Data are the mean f SD (n=3). 
4. DISCUSSION 
In previous papers [ 10,111, we have shown that some 
inflammatory factors including endotoxin, tumor 
necrosis factor, and interleukin-1 stimulated accumula- 
tion of PLA2-II mRNA in cultured rat vascular smooth 
muscle cells and enhanced secretion of PLAz-II from 
the cells. In the present study, using endotoxin- 
administered rat as a model for systemic inflammation, 
we demonstrated for the first time that those responses 
observed in the cultured cells also occurred during in 
vivo inflammation. 
Inhibition studies with anti-PLAz-II antibody in- 
dicate that the PLA2 activity in the endotoxin shock 
plasma and the PLA2 activity released from the tissues 
of endotoxin-challenged rats are attributable to 
Dexametasone - - 
ContrZ Endoto~in 
Fig. 4. Effect of dexamethasone on the increase of PLAa-II mRNA in 
vivo. Rats were injected intraperitoneally with dexamethasone or 
saline, and then injected intravenously with endotoxin or saline 30 
min after administration of dexamethasone. Tissues were removed 
and frozen 24 h after endotaxin challenge. The RNA (10 pg) prepared 
from the tissues was analyzed as described in the legend of Fig. 2. 
25 
Volume 273, number 1,2 FEBSLETTERS October 1990 
PLA2-II. PLAz-II has also been found in some inflam- 
matory sites [12-141. Furthermore, cultured smooth 
muscle cells stimulated with the inflammatory factors 
have been shown to synthesize PLA2-II but not group I 
PLA2 [lo]. Therefore, we concluded that PLAYII is the 
major type of PLAz secreted into extracellular spaces 
during inflammation. 
In septic-shock animals, synthesis of PLA2-II seems 
to be enhanced in many tissues such as the aorta, lung, 
spleen, and thymus. Platelets are also known to be a 
rich source of PLA2-II [19], suggesting that most of the 
PLA2-II in septic-shock serum is the enzyme released 
from platelets. However, during septic shock, the 
number of platelets decreases abruptly and severely 
[20]. Moreover, Murakami et al. [21] have 
demonstrated that activation of platelets in vivo induces 
a rapid and transient increase of plasma PLA2 activity. 
Therefore, the long-term increase of plasma PLA2-II as 
shown in Table I may not be due to the PLA;?-II 
secreted from platelets. PLA2-II in endotoxin shock 
plasma may thus consist of de novo synthesized enzyme 
released from the above tissues. 
Another important finding of this study is the fact 
that accumulation of PLA2-II mRNA in the tissues of 
endotoxin-treated rats is suppressed by glucocorticoid. 
Glucocorticoid inhibits a rise in plasma PLAz activity in 
endotoxin-administered animals [ 11. Thus far, in- 
hibitory activities of glucocorticoids on PLAz action 
have been attributed to enhanced production of 
PLA+hibitory proteins such as lipocortins by the 
agents [22,23]. Thus, one possible explanation of the 
glucocorticoid-mediated ecrease of the PLA2 activity 
in endotoxin-administered animals may be that the 
decrease is due to the enhanced secretion of lipocortins. 
However, our recent study has clarified that glucocor- 
ticoid inhibits the synthesis of PLA2-II in vitro [l 11. 
This result demonstrating that glucocorticoid sup- 
presses the expression of PLA2-II gene in tissues of 
endotoxin-treated rats should lead to new aspects to be 
considered for the in vivo mechanism of glucocorticoid- 
mediated PLAz suppression. 
All the findings described thus far suggest an impor- 
tant role of PLA2-II in inflammatory responses. In fact, 
some studies have shown the pro-inflammatory ac- 
tivities of PLA2 [24,25]. However, biochemical 
evidence on the action of PLA2 is still lacking. In order 
to clarify the role of PLA2-II in inflammation, more 
precise investigation is needed of the PLA2-II attacking 
sites as well as the correlation with the production of 
pro-inflammatory eicosanoids. We are now conducting 
further studies using a highly specific PLA2 inhibitor 
for in vitro and in vivo studies. 
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